secwatch.observer — SEC 8-K summary
======================================

Issuer:     DBV Technologies S.A. (DBVT)
CIK:        0001613780
Form:       8-K
Filed at:   2023-04-20T23:59:59+00:00
Accession:  0001193125-23-106920
Event type: regulatory
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DBV gets FDA path for Viaskin Peanut BLA in toddlers 1-3; EPITOPE efficacy confirmed
--------------------------------------------------------------------------------

- FDA confirmed Phase 3 EPITOPE met primary endpoint; no additional efficacy study required.
- FDA requires new safety study in ~600 toddlers to augment safety data; no food challenge needed.
- Company to submit safety study protocol to FDA by end of Q2 2023; Human Factors study and CMC work ongoing.
- Cash and cash equivalents $192.3M as of March 31, 2023 (down $16.9M from Dec 31, 2022).
- Viaskin Peanut in 1-3 and 4-7 year-olds remain separate product candidates with independent paths.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523106920/0001193125-23-106920-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1613780/000119312523106920/d490619d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-106920

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer